William Garner, MD
Interventional Cardiology · Oklahoma City, OKNPI 1740291517
Payments from drug & device makers
Across 300 payments — averaging $43.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Medtronic$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Abbott$2K
- Novo Nordisk$668
- Johnson & Johnson$646
- plus $3K from 28 others
What the payments were for
- Consulting fees$5004%
- Speaking & faculty fees$2,62520%
- Travel & lodging$2,09616%
- Food & beverage$7,78159%
- Education$1681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $2,709 |
| Medtronic(2 entities) | 12 | $2,378 |
| E.r. Squibb & Sons, L.L.C. | 45 | $1,933 |
| Abbott | 27 | $1,679 |
| Novo Nordisk | 26 | $668 |
| Johnson & Johnson | 57 | $646 |
| Amgen | 21 | $554 |
| Abiomed | 2 | $272 |
| Amarin Pharma, Inc. | 15 | $271 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $268 |
| Philips North America LLC | 5 | $210 |
| Astellas Pharma US Inc | 3 | $181 |
| Cvrx, Inc. | 2 | $151 |
| Impulse Dynamics (USA) Inc. | 2 | $139 |
| AstraZeneca | 9 | $133 |
| Siemens Medical Solutions USA, Inc. | 1 | $111 |
| Esperion Therapeutics, Inc. | 8 | $103 |
| Kestra Medical Technology Services, Inc. | 3 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Chiesi USA, Inc. | 3 | $77 |
| Merck | 6 | $77 |
| Novartis | 4 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Boehringer Ingelheim | 3 | $58 |
| Baxter Healthcare | 1 | $58 |
| Boston Scientific | 2 | $33 |
| Veryan Medical Incorporated | 2 | $33 |
| Kerecis Limited | 1 | $25 |
| Endologix LLC | 1 | $24 |
| Braemar Manufacturing, LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$3,125
- Advisa$2,096
- CAMZYOS$581
- Optis Coronary Imaging System$307
- Impella$272
- Repatha$248
- Ozempic$240
- JETI$238
- Perclose ProGlide suture mediated closure system$141
- JETi Peripheral Catheter$139
- PERCLOSE PROGLIDE$139
- OPTIMIZER SMART SYSTEM$125
- IGT D Peripheral$120
- Artis Q$111
- Barostim Neo System$103
How this compares
$13,170 in reported general payments places this provider in the 65th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $225,502 |
| XareltoRivaroxaban | 97 | $93,021 |
| MultaqDronedarone Hcl | 41 | $47,702 |
| OzempicSemaglutide | 31 | $33,466 |
| Repatha SureclickEvolocumab | 49 | $26,307 |
| EntrestoSacubitril/Valsartan | 21 | $18,286 |
| FarxigaDapagliflozin Propanediol | 20 | $16,777 |
| VascepaIcosapent Ethyl | 16 | $6,793 |
| Flecainide Acetate | 139 | $6,495 |
| Metoprolol Succinate | 415 | $5,021 |
| Atorvastatin Calcium | 277 | $4,141 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 25 | $4,101 |
| Icosapent Ethyl | 11 | $3,825 |
| Rosuvastatin Calcium | 248 | $3,570 |
| ClopidogrelClopidogrel Bisulfate | 323 | $3,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,709 | $225,502253 claims |
| Johnson & JohnsonXarelto | $646 | $93,02197 claims |
| Sanofi-aventis U.S. LLCMultaq | $82 | $47,70241 claims |
| Novo NordiskOzempic | $668 | $33,46631 claims |
| NovartisEntresto | $63 | $18,28621 claims |
| AstraZenecaFarxiga | $133 | $16,77720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- Naeem TahirkheliOklahoma City$8.6M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Usman BaberOklahoma City$736K
- Jeffrey SparlingOklahoma City$381K
- Thomas McGarryOklahoma City$153K
- Faisal LatifOklahoma City$129K
- Branislav SchifferdeckerOklahoma City$121K
- Mazen Abu-FadelOklahoma City$98K
- Dwayne SchmidtOklahoma City$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.